American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6402)
  2. Solid Tumor Oncology Division (5540)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1638)
  6. Epidemiology and Biostatistics (1495)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1354)
  10. Hematologic Malignancies, Division of (1282)
Search Within
Formats
  1. Meeting Abstract (6344)
  2. Journal Article (2584)
  3. Editorial (76)
  4. Review (68)
  5. Guidelines (55)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6402)
  2. Solid Tumor Oncology Division (5540)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1638)
  6. Epidemiology and Biostatistics (1495)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (291)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8707)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (10)

More Publications

Results (9183)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
    Meeting Abstract

    Lin, J. J.; Tan, D. S. W.; Kummar, S.; Patel, J. D.; Cermignani, L.; Dai, M. S.; Lassen, U. N.; Leyvraz, S.; Liu, Y.; Moreno, V.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study
    Meeting Abstract

    Paik, P. K.; Garassino, M. C.; Le, X.; Thomas, M.; Sakai, H.; Veillon, R.; Smit, E. F.; Mazieres, J.; Cortot, A. B.; Raskin, J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions
    Meeting Abstract

    Nguyen, D.; Shum, E.; Baik, C. S.; Janne, P. A.; Patel, J. D.; Schenk, E. L.; Shibata, Y.; Yu, H. A.; Albayya, F.; Pearson, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors
    Meeting Abstract

    Cooper, A. J.; Drilon, A. E.; Rotow, J. K.; Liu, S. V.; Gautschi, O.; Smith, K. E. R.; Lee, D. H.; Nagasaka, M.; Loong, H. H. F.; Pennell, N. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Analytical and clinical validation of oncomine Dx target (ODxT) test and local testing for identifying patients with HER2 (ERBB2)-mutant (HER2m) non–small-cell lung cancer (NSCLC) for treatment with trastuzumab deruxtecan (T-DXd) in DESTINY-Lung01/02 (DL-01/02)
    Meeting Abstract

    Li, B. T.; De Langen, A.; Goto, K.; Vitazka, P.; Qi, Z.; Ha, T.; Velasco Roth, A. M.; Karnoub, M.; Feng, W.; Pereira, K.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Initial chemotherapy for locally advanced and metastatic NUT carcinoma: A report from the NUT carcinoma registry
    Meeting Abstract

    Luo, J.; Lee, E.; Sanchez, M.; Finstein, B.; Hertzler, H.; Luong, N.; Tamen, R.; Nguyen, T.; Paik, P. K.; Chaft, J. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting
    Meeting Abstract

    Yang, M.; MacEwan, J. P.; Sriteja Boppudi, S.; McClain, M.; O'Hara, R.; Liu, F.; Paik, P. K.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2 -mutant non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Liu, S. Y.; Jee, J.; Santini, F. C.; Schoenfeld, A. J.; Eichholz, J.; Johnson, K.; Martinez, A.; Guo, J.; Riaz, N.; Lee, N. Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Rosner, S.; Sivapalan, L.; Zahurak, M.; Thummalapalli, R.; Rayes, R.; Connor, S.; Sanber, K.; Reuss, J. E.; Pereira, G.; Smith, K. N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors
    Meeting Abstract

    Hassan, R.; Butler, M. O.; Oh, D. Y.; O'Cearbhaill, R. E.; MacMullen, L.; Jeter, E.; Guha, U.; Muzithras, V. P.; Zikaras, K.; Johnson, M. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save